Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Response Assessment to HIPEC for Peritoneal Carcinomatosis
NCT04847063Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2021
- Primary completion
- Dec 2033
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oxaliplatin, mitomycin c, cisplatin and doxorubicin in peritoneal carcinomatosis (PC), peritoneal mesothelioma, ovarian cancer and 2 more (4 arms), sponsored by National Cancer Institute. Primary endpoint: Correlation between ex vivo simulated HIPEC and in vivo HIPEC with respect to percent necrosis and Ki-67. Started Oct 2021; status: recruiting.
02
Drugs
oxaliplatinmitomycin ccisplatindoxorubicin
03
Conditions
peritoneal carcinomatosis (PC)peritoneal mesotheliomaovarian cancercolorectal cancer (CRC)appendiceal cancer
Beyond the preview
Go deeper on NCT04847063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847063.